Phaseline

Companies › Nanjing Immunophage Biotech

Nanjing Immunophage Biotech: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IPG1094
Macrophage migration inhibitory factor (MIF) inhibitor
MIFPhase 1Healthy Volunteers; Solid TumorJan 2027
IPG7236–Phase 1Advanced Solid TumorDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07679113IPG1094Phase 1Healthy VolunteersOtherJan 2027
NCT06212076IPG1094Phase 1Solid TumorOncologyJul 2027
NCT07508761IPG7236Phase 1Advanced Solid TumorOncologyDec 2028

Targets

MIF (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.